Back to search results
NCT06723015

Tau PET Outcomes With Anti-amyloid Immunotherapies

Enrolling by Invitation
PHASE2Ages 50–90Interventional
Mayo Clinic
~135 participants
Updated 2025-11-18 on ClinicalTrials.gov
What's tested:18F-AV-1451

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in tau PET Standardized Uptake Value (SUVR)
Measured over Baseline, 18 months

Conditions

Cognitive Impairment, Mild
Dementia, Mild
Alzheimer Disease

Explore related trials

Alzheimer's DiseaseMild cognitive disorderMild dementiaAmyloid

NCT06723015

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Petrice Cogswell, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 50-90 years
Male or female
Mild cognitive impairment due to AD or mild AD
Amyloid positive via CSF or PET
Meets other eligibility criteria for anti-amyloid immunotherapy
Subject or delegate provides informed consent

Exclusion

Subjects unable to lie down without moving for 10 minutes.
Women who are pregnant or cannot stop breast feeding for 24 hours.
Claustrophobic patients unable to tolerate the scans (no sedation can be offered).

What this trial measures

  • Change in tau PET Standardized Uptake Value (SUVR)Baseline, 18 months

    A PET Standardized Uptake Value (SUV) is measured by calculating the ratio of the radioactivity concentration within a specific region of interest (ROI) on a PET scan, divided by the injected dose of the radiotracer per unit of the patient's body weight. The calculated Standardized Uptake Value (SUVR) is reported as a single number, with higher values indicating greater tracer uptake in the target region relative to the reference region